Inclusion Criteria:

        Male or female at least 18 years of age.

        Confirmed diagnosis of CML

        Is at least 18 months from CML diagnosis.

        Current concomitant treatment with TKI therapy (Imatinib, Dasatinib, Nilotinib or
        Bosutinib; excluding Ponatinib).

        One of the following confirmed:

          1. break point cluster ( BCR)-ABL Polymerase chain reaction (PCR) at stable molecular
             disease (e.g., Major Molecular Response (MMR) stable but not Complete Molecular
             Response (CMR) or;

          2. HR but no MMR.

        Stable molecular response defined as 2 sequential BCR-ABL levels done in the same lab with
        less than one-half log reduction of BCR-ABL (BA)

        Eastern Cooperative Oncology Group (ECOG) Performance Score of less than 3

        Absolute neutrophil count greater than or equal to 500 cells/mm^3

        Platelet count greater than or equal to 50,000 cells/mm^3

        Serum bilirubin less than or equal to 1.5 times the upper limit of normal

        Alanine transaminase (ALT) and Aspartate transaminase (AST) less than or equal to 2.5 times
        the upper limit of normal

        Alkaline phosphatase less than or equal to 2.5 times the upper limit of normal

        Not pregnant. Females of child bearing potential must use a medically accepted method of
        contraception and must agree to continued use of this method for the duration of the study
        and for 30 days after last dose of study drug.

        Male subjects capable of producing offspring, must use a medically accepted method of birth
        control and agree to continued use of this method for the duration of the study and for 30
        days after last dose of study drug because of the possible effects on spermatogenesis

        Exclusion Criteria:

        Known additional malignancy requiring active treatment

        Active infection requiring antibiotic treatment.

        Known i.e. previously documented HIV, Hepatitis B, or Hepatitis C infection.

        Known symptomatic congestive heart failure, unstable angina or cardiac arrhythmia.

        Current concomitant use of non NSAIDs (including Aspirin) or cyclooxygenase-1 (COX-1); a
        washout period of 4 weeks prior to enrollment is permitted.

        Known non-compliance with medications.

        In the opinion of a PI or Sub-I, an uncontrolled medical or psychiatric disorder.

        Active central nervous system leukemia.

        Preceding allogeneic stem hematopoietic stem cell transplant.

        Known T315I mutation.

        Current concomitant use of fish oil at EPA dose greater than 500 mg; a washout period of 4
        weeks prior to enrollment is permitted.

        Known hypersensitivity to EPA.

        Pregnant or breastfeeding